Detail akcie Bio-Techne online

Business Summary: Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
Financial Summary: BRIEF: For the nine months ended 31 March 2026, BIO-TECHNE Corp revenues decreased 1% to $893.8M. Net income applicable to common stockholders increased 40% to $127.2M. Revenues reflect Diagnostics and Genomics segment decrease of 4% to $246.2M, Protein Sciences segment decrease of less than 1% to $643.4M, United States segment decrease of 7% to $469.3M. Net income reflects Corporate and Other segment loss decrease of 30% to $112.3M.